This page shows the latest Karyopharm news and features for those working in and with pharma, biotech and healthcare.
Biogen has agreed a deal to license a brain disease candidate from Karyopharm for $10m upfront, and up to $217m in milestone payments.
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Option, licence. 223. Karyopharm Therapeutics/ Biogen. Oral SINE compound KPT-350 (IND ready) other assets for neurological and neurodegenerative conditions.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...